Clinical Trial: DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07070440) titled 'DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)' on June 16.

Brief Summary: This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer

Intervention: DRUG: DZD6008

DZD6008 was administered orally at 40/60/90 mg QD.

DRUG: Pemetrexed

Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.

DRUG: Carboplatin

Carbopl...